Trial Profile
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide
- Indications Churg-Strauss syndrome
- Focus Therapeutic Use
- Acronyms REOVAS
- 13 Apr 2021 Status changed from recruiting to completed.
- 12 Dec 2016 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 12 Dec 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.